3D comparison of low, intermediate, and advanced hippocampal atrophy in MCI

Hum Brain Mapp. 2010 May;31(5):786-97. doi: 10.1002/hbm.20905.

Abstract

We applied the hippocampal radial atrophy mapping technique to the baseline and follow-up magnetic resonance image data of 169 amnestic mild cognitive impairment (MCI) participants in the imaging arm of the Alzheimer's Disease Cooperative Study MCI Donepezil/Vitamin E trial. Sixty percent of the subjects with none to mild hippocampal atrophy rated with the visual medial temporal atrophy rating scale (MTA score < 2) and 33.8% of the subjects with moderate to severe (MTA > or = 2) hippocampal atrophy converted to Alzheimer's disease (AD) during 3-year follow-up. MTA > or = 2 showed a trend for greater left sided hippocampal atrophy versus MTA < 2 groups at baseline (P(corrected) = 0.08). Higher MTA scores were associated with progressive atrophy of the subiculum and the CA1-3 subregions. The MTA < 2 group demonstrated significant bilateral atrophy progression at follow-up (left P(corrected) = 0.008; right P(corrected) = 0.05). Relative to MTA < 2 nonconverters, MTA < 2 converters showed further involvement of the subiculum and CA1 and additional involvement of CA2-3 at follow-up. Right CA1 atrophy was significantly associated with conversion to dementia (for 1 mm greater right CA1 radial distance subjects had 50% reduced hazard for conversion). Greater CA1 and subicular atrophy can be demonstrated early and is predictive of future conversion to AD, whereas CA2-3 involvement becomes more evident as the disease progresses.

Publication types

  • Clinical Trial
  • Comparative Study
  • Multicenter Study
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Alzheimer Disease / drug therapy
  • Alzheimer Disease / pathology*
  • Atrophy
  • Cognition Disorders / drug therapy
  • Cognition Disorders / pathology*
  • Disease Progression
  • Female
  • Follow-Up Studies
  • Functional Laterality
  • Hippocampus / pathology*
  • Humans
  • Imaging, Three-Dimensional
  • Longitudinal Studies
  • Magnetic Resonance Imaging
  • Male
  • Nootropic Agents / therapeutic use
  • Severity of Illness Index
  • Vitamin E / therapeutic use

Substances

  • Nootropic Agents
  • Vitamin E